The financing will support the advancement of Akero's lead clinical candidate AKR-001, a novel, long-acting fibroblast growth factor 21 (FGF21) analog, through Phase 2 clinical development in patients with non-alcoholic steatohepatitis (NASH), scaling of the company's manufacturing capabilities, and expansion of Akero's therapeutic pipeline in metabolic disease.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

400 Technology Sq. 10th Floor
Cambridge, MA 02139
USA

Phone

Undisclosed

Website

www.akerotx.com

Email Address

[email protected]

Overview

Akero Therapeutics (Nasdaq: AKRO) is committed to providing meaningful treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the liver and liver cell damage resulting in fibrosis, cirrhosis, liver failure and death.

Profile

Social Media

Akero Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Andrew Cheng

Chief Operating Officer

Jonathan Young

Chief Scientific Officer

Timothy Rolph

VP - Bus. Development

Kitty Yale

Browse more venture capital transactions:

Prev: 12/13/2018: LiquidPiston venture capital transaction
Next: 12/13/2018: InterVenn BioSciences venture capital transaction

Share this article

Where The Data Comes From

We do our best to record funding rounds that are announced publicly. VC transactions reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary